QPS ups capacity to support large-scale Ph III trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/alphaspirit)
(Image: iStock/alphaspirit)
QPS Holdings, LLC is investing in personnel and laboratory capacity for translational medicine at its headquarters in Delaware Technology Park.

According to the contract research organization (CRO), the expansion will enable it to process high sample volumes for Phase III clinical trials.

The investment is expected to result in a laboratory staff of 88, up from 57. The number of analysis teams will also increase from seven to 11.

Additionally, the CRO has created a working group to handle the demand for neutralizing antibody assays, according to QPS.

In line with the additions, the company has also expanded its dedicated immunobioanalysis and cell culture space, as well as the protein mass spectrometry area.

The company’s laboratories and testing facilities are located its headquarters in Newark, DE; Springfield, MO; Fargo, ND; Hollywood, FL; South Miami, FL, USA; Groningen, The Netherlands; Graz, Austria; Hyderabad, India; Barcelona, Spain; and Taipei, Taiwan.

Related topics: Preclinical Research, Phase III-IV

Related news

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers